FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	7110		
Machinaton	D C 2	2540	

OMB APPROVAL 37 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lu Hongbo				2. Issuer Name and Ticker or Trading Symbol Zenas BioPharma, Inc. [ZBIO]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
	NAS BIOP	HARMA, INC.	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 09/13/2024										Officer (give title below)		Other (specify below)	
(Street) WALTH	AM M)2451 Zip)		4. If A	Amend	ment,	Date o	of Origin	al File	d (Month/Da	y/Year)		6. Ind Line)	Form	filed by O	ne Re	ng (Check porting Per an One Re	son
		Table	l - No	n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or B	Benefi	ciall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)				4 and Securit		ies Form cially (D) or Following (I) (In		: Direct Indirect str. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)				
									Code	v	Amount	(A) o (D)	Pric	:e	Transact (Instr. 3	tion(s)			(IIISU. 4)
Common Stock 09/13/2				024 P 58,823			A	\$	17	58,823 I				See footnote ⁽¹⁾					
		Та	ble II -								osed of, convertib				Owne	d			
1. Title of Derivative Conversion or Exercise Price of Derivative Security		tion Date,	4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Disport of (D	r osed) r. 3, 4	6. Date Expirat (Month	tion Da			int of ities rlying ative ity (Inst	De Se (In	Price of rivative curity estr. 5)	itive derivative		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficia Ownershi ct (Instr. 4)		
					Code				Date Exercisable		Expiration		Amour or Number of						

Explanation of Responses:

1. The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Hongbo Lu, By /s/ Hongbo Lu 09/17/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.